Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.

MLA

Prondzynski, Maksymilian, et al. “Disease Modeling of a Mutation in α-Actinin 2 Guides Clinical Therapy in Hypertrophic Cardiomyopathy.” EMBO Molecular Medicine, vol. 11, no. 12, Dec. 2019, p. e11115. EBSCOhost, https://doi.org/10.15252/emmm.201911115.

APA

Prondzynski, M., Lemoine, M. D., Zech, A. T., Horváth, A., Di Mauro, V., Koivumäki, J. T., Kresin, N., Busch, J., Krause, T., Krämer, E., Schlossarek, S., Spohn, M., Friedrich, F. W., Münch, J., Laufer, S. D., Redwood, C., Volk, A. E., Hansen, A., Mearini, G., … Carrier, L. (2019). Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy. EMBO Molecular Medicine, 11(12), e11115. https://doi.org/10.15252/emmm.201911115

Chicago

Prondzynski, Maksymilian, Marc D Lemoine, Antonia Tl Zech, András Horváth, Vittoria Di Mauro, Jussi T Koivumäki, Nico Kresin, et al. 2019. “Disease Modeling of a Mutation in α-Actinin 2 Guides Clinical Therapy in Hypertrophic Cardiomyopathy.” EMBO Molecular Medicine 11 (12): e11115. doi:10.15252/emmm.201911115.